Incident Report
Subform I: General Information
1. Report Type.
New incident report
Incident Report Number: 2017-7507
2. Registrant Information.
Registrant Reference Number: 20171110
Registrant Name (Full Legal Name no abbreviations): Bayer CropScienc Inc
Address: Suite 200, 160 Quarry Park Blvd SE
City: Calgary
Prov / State: AB
Country: Canada
Postal Code: T2C 3G3
3. Select the appropriate subform(s) for the incident.
Scientific Study
4. Date registrant was first informed of the incident.
5. Location of incident.
6. Date incident was first observed.
Product Description
7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.
Active(s)
PMRA Registration No. 30221
PMRA Submission No.
EPA Registration No. 264-1106
Product Name: INDAZIFLAM 200 SC HERBICIDE
7. b) Type of formulation.
Application Information
8. Product was applied?
Unknown
9. Application Rate.
10. Site pesticide was applied to (select all that apply).
11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).
To be determined by Registrant
12. In your opinion, was the product used according to the label instructions?
Unknown
Subform VII: Scientific Study
1. Study Reference
Title Toxicity of indaziflam SC 200 to duckweed (Lemna gibba G3) under static-renewal conditions - Final report
Date 12-SEP-17
2. a) Is an extension needed to translate the document?
No
3. Type of incident identified in the study
Increased health or environmental risk
4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)
BCS is submitting new information to PMRA related to indaziflam technical. This information is not necessarily a new adverse effect of the subject chemical, but is rather new information submitted for the Agencys own review and evaluation because the data meet the Agencys administrative reporting criteria.
5. a) Was the study discontinued before completion?
No
5. b) Provide the reason for discontinuation
6. If the study is ongoing, what is the expected completion date?
For Registrant use only
7. Provide supplemental information here